Bessemer Group Inc. Buys 9,320 Shares of CVS Health Corporation $CVS

Bessemer Group Inc. boosted its stake in CVS Health Corporation (NYSE:CVS) by 34.9% in the first quarter, Holdings Channel reports. The firm owned 35,994 shares of the pharmacy operator’s stock after purchasing an additional 9,320 shares during the quarter. Bessemer Group Inc.’s holdings in CVS Health were worth $2,585,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. State Street Corp increased its position in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after acquiring an additional 1,245,457 shares during the period. Capital International Investors raised its position in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares during the last quarter. Norges Bank bought a new position in shares of CVS Health during the fourth quarter worth about $1,666,265,000. Finally, Morgan Stanley lifted its position in shares of CVS Health by 6.3% in the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after purchasing an additional 1,211,631 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Up 2.6%

CVS opened at $110.40 on Wednesday. The company has a market cap of $140.87 billion, a PE ratio of 48.64, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $110.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company has a 50 day moving average of $99.58 and a 200 day moving average of $85.58.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Thursday, July 23rd. CVS Health’s payout ratio is 117.18%.

Insider Activity

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by company insiders.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced that common prescription medications for dogs and cats are now available at its roughly 9,000 CVS Pharmacy locations nationwide, expanding the chain’s role beyond human prescriptions and potentially adding a small but incremental revenue stream while increasing store traffic. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Market commentary highlighted that CVS has been outperforming the broader market, reflecting continued investor confidence in the company’s ongoing operational improvement and turnaround efforts. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Positive Sentiment: Another report echoed the same outperformance theme, noting CVS’s strong trading versus the market and suggesting that investors remain focused on the company’s improving fundamentals. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: A longer-form analysis argued CVS is still in the middle of a meaningful turnaround, with improving margins, declining leverage, and strong cash flow, but it also noted the stock is no longer viewed as a deep bargain after its rally. CVS Health Update: The C- Student Now Pulling Down A B+

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CVS. HSBC reissued a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. UBS Group raised their price objective on shares of CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. JPMorgan Chase & Co. lifted their target price on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Mizuho boosted their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Finally, Barclays boosted their price objective on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.